EGFR and non-small cell lung carcinoma: The approval was based on the FLAURA trial which demonstrated that, in previously-untreated EGFR mutation-positive NSCLC, median progression-free survival (osimertinib = 18.9 months, comparator = 10.2 months, hazard ratio = 0.46) and overall survival (osimertinib = 38.6 months, comparator = 31.8 months, hazard ratio = 0.80) were longer among patients receiving osimertinib compared with standard EGFR-TKIs [4, 16].